01 10Sulperazon
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 684
2018 Revenue in Millions : 613
Growth (%) : 12
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 618
2019 Revenue in Millions : 684
Growth (%) : -10
Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 683
2020 Revenue in Millions : 618
Growth (%) : 11
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 786
2021 Revenue in Millions : 683
Growth (%) : 15
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 757
2022 Revenue in Millions : 786
Growth (%) : -4
Main Therapeutic Indication : Urology
Currency : USD
2014 Revenue in Millions : 14.90%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Urology
Currency : USD
2015 Revenue in Millions : 354
2014 Revenue in Millions : 339
Growth (%) : -4%
Main Therapeutic Indication : Urology
Currency : USD
2016 Revenue in Millions : 396
2015 Revenue in Millions : 339
Growth (%) : 17
Main Therapeutic Indication : Urology
Currency : USD
2017 Revenue in Millions : 471
2016 Revenue in Millions : 396
Growth (%) : 19
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 613
2017 Revenue in Millions : 471
Growth (%) : 30%
LOOKING FOR A SUPPLIER?
